The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 20 July 2004, www.theannals.com, DOI 10.1345/aph.1D638.
 The Annals of Pharmacotherapy: Vol. 38, No. 9, pp. 1389-1394. DOI 10.1345/aph.1D638
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Periclou, A. P
Right arrow Articles by Abramowitz, W. T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Periclou, A. P
Right arrow Articles by Abramowitz, W. T

ALZHEIMER'S DISEASE

Lack of Pharmacokinetic or Pharmacodynamic Interaction Between Memantine and Donepezil

Antonia P Periclou, PhD

Principal Scientist, Clinical Pharmacology and Drug Dynamics, Forest Research Institute, Jersey City, NJ

Daniel Ventura, PhD

Director, CNS Therapeutic Area, Forest Research Institute

Tyler Sherman, RPh CCRA

Field Monitor, Clinical Pharmacology and Drug Dynamics, Forest Research Institute

Niranjan Rao, PhD

Director, Clinical Pharmacology and Drug Dynamics, Forest Research Institute

Wattanaporn T Abramowitz, PhD

Executive Director, Clinical Pharmacology and Drug Dynamics, Forest Research Institute

Reprints: Antonia P Periclou PhD, Forest Research Institute, Harborside Financial Center, Plaza V, 19th Fl., Jersey City, NJ 07311-4994, fax 201/427-8100, Antonia.Periclou{at}frx.com

BACKGROUND: Memantine, a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist, was approved in the US for treatment of moderate to severe Alzheimer's disease in October 2003.

OBJECTIVE: To determine whether an in vivo pharmacokinetic interaction exists between memantine and the acetylcholinesterase (AChE) inhibitor donepezil.

METHODS: In this open-label, multiple-dose study, 24 healthy subjects (aged 18–35 y) received oral administration of memantine 10 mg on day 1. Following a 14-day washout period, subjects were orally administered donepezil 5 mg once daily for 7 days on an outpatient basis. Beginning on day 22, the donepezil dosage was doubled for 22 days to the target dose of 10 mg once daily, with the last donepezil dose concomitantly administered with memantine 10 mg on day 43. Assessments included pharmacokinetic as well as safety parameters. In addition, AChE inhibition was measured in red blood cells by radiolabeled-enzyme assay following administration of donepezil alone and after a single memantine dose.

RESULTS: Data from 19 subjects who completed the study indicated no significant pharmacokinetic interactions between a single dose of memantine and multiple doses of donepezil. Percent maximum inhibition of AChE activity (mean ± SD) by donepezil was 77.8 ± 7.3% and not significantly different upon coadministration of a single dose of memantine (81.1 ± 5.7%). Two subjects withdrew due to adverse events while taking donepezil alone. Single memantine doses administered with multiple donepezil doses were well tolerated.

CONCLUSIONS: The pharmacokinetic and pharmacodynamic data from this study indicated a lack of interaction between memantine and donepezil, suggesting that memantine and donepezil may be safely and effectively used in combination.

Key Words: Alzheimer's disease, donepezil, memantine

Published Online, July 20, 2004. www.theannals.com, DOI 10.1345/aph.1D638




homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.